Sarepta Therapeutics (SRPT) Stock Price, Quote, News & History

Q: What sector and industry does Sarepta Therapeutics (SRPT) operate in?

Sarepta Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Sarepta Therapeutics (SRPT) Stock Price, Quote, News & History

SRPTNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$17.03

At close: Feb 6, 4:00 PM EST

$17.20

0.171.00%

After Hours: 7:57 PM EST

Overview

News Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

-

Close

-

Volume / Avg.

0 / 3.48M

Day Range

- - -

52 Wk Range

10.42 - 120.05

Market Cap

$1.80B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

25

Short Interest

22.63%

Days to Cover

7.72

Recent Sarepta Therapeutics Inc News

Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday?

Natural gas jumps over 30% on winter storm disruptions, silver posts its biggest daily surge since 2008, and stocks grind higher.

Piero Cingari

Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday

Avi Kapoor

Sarepta Says Elevidys Slows Duchenne Progression After Three Years

Sarepta's Elevidys shows significant improvement in motor function measures after three years of treatment, with no new safety signals.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-244.64M

Investing Cash Flow (TTM)

737.55M

Financing Cash Flow (TTM)

-80.15M

Free Cash Flow (TTM)

-388.84M

Capital Expenditure (TTM)

-144.20M

Net Change in Cash (TTM)

412.77M

Analyst Trends and Forecast

1

Oct 25

3

2

Nov 25

1

Dec 25

1

2

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.4

Sell

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.18B

PE Ratio (TTM)

-

PE Ratio (FWD)

13.11

PEG Ratio (TTM)

-

PS Ratio (TTM)

0.78

PB Ratio (TTM)

1.35

Earnings Yield % (TTM)

-16.62%

Earnings Yield % (FWD)

7.63%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$12.60

Company Debt

Total Debt

$1.04B

LT Debt

$1.04B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$127.52M

Total Cash

$613.08M

Debt to Equity

0.95

Issuance of Debt (TTM)

-$127.52M

Repayment of Debt (TTM)

-$127.52M

Key Statistics

Open

-

Close

-

Volume / Avg.

0 / 3.48M

Day Range

- - -

52 Wk Range

10.42 - 120.05

Market Cap

$1.80B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

25

Short Interest

22.63%

Days to Cover

7.72

About

Sector

Health Care

Industry

Biotechnology

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targ...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Sarepta Therapeutics (SRPT) stock?

A

You can purchase shares of Sarepta Therapeutics (NASDAQ:SRPT) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Sarepta Therapeutics (SRPT) competitors?

A

Other companies in Sarepta Therapeutics’s space includes: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Syndax Pharmaceuticals Inc (NASDAQ:SNDX), Ascentage Pharma Group International (NASDAQ:AAPG), Mesoblast Ltd (NASDAQ:MESO) and Sionna Therapeutics Inc (NASDAQ:SION).

Q

What is the forecast, or price target, for Sarepta Therapeutics (SRPT) stock?

A

Sarepta Therapeutics has a consensus price target of $25.76.

Q

What is the current price for Sarepta Therapeutics (SRPT)?

A

The stock price for Sarepta Therapeutics (NASDAQ: SRPT) is $17.2 last updated February 5, 2026 at 7:57 PM EST.

Q

Does Sarepta Therapeutics (SRPT) pay a dividend?

A

There are no upcoming dividends for Sarepta Therapeutics.

Q

When is Sarepta Therapeutics (NASDAQ:SRPT) reporting earnings?

A

Sarepta Therapeutics does not have any upcoming earnings scheduled.

Q

Is Sarepta Therapeutics (SRPT) going to split?

A

There is no upcoming split for Sarepta Therapeutics.

Q

What sector and industry does Sarepta Therapeutics (SRPT) operate in?

A

Sarepta Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Ultragenyx Pharmaceutical Inc

NASDAQ:RARE

$23.50

-1.22%

Syndax Pharmaceuticals Inc

NASDAQ:SNDX

$20.11

-0.20%

Ascentage Pharma Group International

Sionna Therapeutics Inc

NASDAQ:SION

$35.95

1.99%

Olema Pharmaceuticals inc

NASDAQ:OLMA

$25.00

-0.04%

Nurix Therapeutics Inc

NASDAQ:NRIX

$15.95

%

Stoke Therapeutics Inc

NASDAQ:STOK

$29.85

-2.07%

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

-

Close

-

Volume / Avg.

0 / 3.48M

Day Range

- - -

52 Wk Range

10.42 - 120.05

Market Cap

$1.80B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

25

Short Interest

22.63%

Days to Cover

7.72

Recent Sarepta Therapeutics Inc News

Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday?

Natural gas jumps over 30% on winter storm disruptions, silver posts its biggest daily surge since 2008, and stocks grind higher.

Piero Cingari

Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday

Avi Kapoor

Sarepta Says Elevidys Slows Duchenne Progression After Three Years

Sarepta's Elevidys shows significant improvement in motor function measures after three years of treatment, with no new safety signals.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-244.64M

Investing Cash Flow (TTM)

737.55M

Financing Cash Flow (TTM)

-80.15M

Free Cash Flow (TTM)

-388.84M

Capital Expenditure (TTM)

-144.20M

Net Change in Cash (TTM)

412.77M

Analyst Trends and Forecast

1

Oct 25

3

2

Nov 25

1

Dec 25

1

2

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.4

Sell

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.18B

PE Ratio (TTM)

-

PE Ratio (FWD)

13.11

PEG Ratio (TTM)

-

PS Ratio (TTM)

0.78

PB Ratio (TTM)

1.35

Earnings Yield % (TTM)

-16.62%

Earnings Yield % (FWD)

7.63%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$12.60

Company Debt

Total Debt

$1.04B

LT Debt

$1.04B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$127.52M

Total Cash

$613.08M

Debt to Equity

0.95

Issuance of Debt (TTM)

-$127.52M

Repayment of Debt (TTM)

-$127.52M

Key Statistics

Open

-

Close

-

Volume / Avg.

0 / 3.48M

Day Range

- - -

52 Wk Range

10.42 - 120.05

Market Cap

$1.80B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

25

Short Interest

22.63%

Days to Cover

7.72

About

Sector

Health Care

Industry

Biotechnology

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targ...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry